Welcome to our dedicated page for Third Harmonic Bio news (Ticker: THRD), a resource for investors and traders seeking the latest updates and insights on Third Harmonic Bio stock.
Third Harmonic Bio, Inc. (THRD) generated news primarily as a clinical-stage biopharmaceutical company focused on dermal, respiratory, and gastrointestinal inflammatory diseases driven by mast cells. Its disclosures describe a research and development strategy centered on novel, highly selective, small-molecule inhibitors of KIT, a cell surface receptor that regulates mast cell function and survival. The company’s news flow highlighted progress and decisions around its lead KIT inhibitor programs and subsequent corporate actions.
Earlier news items focused on the clinical development of THB335, a titratable, oral small molecule inhibitor of KIT. Releases covered the design and progress of a Phase 1 single and multiple ascending dose trial in healthy volunteers, including safety, pharmacokinetics, and pharmacodynamic effects measured through reductions in serum tryptase, a biomarker of mast cell activation. Updates also addressed Phase 2 readiness activities in chronic spontaneous urticaria, including completion of clinical, toxicology, and manufacturing work to support a potential Phase 2 trial.
Financial and corporate updates formed another major category of news. Third Harmonic Bio reported quarterly and annual financial results, describing research and development spending trends, the shift away from its THB001 program, and what it characterized as a strong cash and cash equivalents position. The company also issued releases about participation in healthcare and investor conferences, where management discussed its development programs and strategic outlook.
Later news items document a significant strategic shift. Third Harmonic Bio announced a strategic review process to explore potential strategic transactions and business combinations, halted non-THB335 research activities, and implemented workforce reductions. Subsequent releases described the board’s approval of a Plan of Liquidation and Dissolution, stockholder approval of the plan, expected liquidation distributions to stockholders, and the initiation of a sale process for THB335 and related intellectual property.
For readers researching THRD, this news archive provides a record of Third Harmonic Bio’s clinical data disclosures, financial reporting, strategic reviews, and ultimately its decision to liquidate and dissolve, including the steps toward delisting and winding down operations.
Summary not available.
Summary not available.
Third Harmonic Bio (THRD) reported its financial results for the fourth quarter and full year ended December 31, 2022. The company has a robust cash position of $288.9 million, sufficient to support operations for at least the next twelve months. Research and development expenses rose to $9.3 million in Q4 2022, up from $4.3 million in Q4 2021, and full-year R&D expenses increased to $24.4 million, compared to $15.7 million in 2021. Although the company achieved a decrease in net loss to $11.5 million for Q4 2022, the full-year net loss was $35.2 million, up from $29.6 million in 2021. The company is progressing towards selecting a next-generation KIT inhibitor candidate.
Third Harmonic Bio (THRD) announced the discontinuation of its Phase 1b study of THB001 due to asymptomatic liver transaminitis observed in two subjects at the 200mg BID dose. Although disappointing, preliminary analyses indicate clinical activity at this dose. The company is prioritizing patient safety and will conduct nonclinical studies to investigate the liver effects. In 2023, THRD aims to nominate a new development candidate from its next-generation oral wild-type KIT inhibitors.
Third Harmonic Bio (Nasdaq: THRD) successfully completed an upsized IPO, raising approximately $213.1 million to advance its THB001 treatment for chronic hives and asthma. The company has begun dosing patients in its Phase 1b trial for chronic inducible urticaria and plans to initiate an asthma trial in 2023. As of September 30, 2022, it had cash and equivalents of $299.5 million, sufficient to fund operations through 2025. While R&D expenses rose, G&A expenses significantly increased due to personnel costs and the IPO, leading to a net loss of $8.2 million in Q3 2022, versus $7.4 million in Q3 2021.
Third Harmonic Bio (Nasdaq: THRD) has closed its initial public offering of 12,535,000 shares at $17.00 per share, raising approximately $213.1 million in gross proceeds. This includes the full exercise of the underwriters' option for an additional 1,635,000 shares. The shares began trading on the Nasdaq Global Market on September 15, 2022. Morgan Stanley, Jefferies, and Cowen acted as joint bookrunning managers for this offering, which aims to support the development of its lead product, THB001, a selective oral KIT inhibitor for severe inflammatory diseases.